Evidence map›Paper›PMID 36688536›Full record

ArticleeLife2023

Soluble amyloid-β precursor peptide does not regulate GABA

Pascal Dominic Rem, Vita Sereikaite, Diego Fernández-Fernández, Sebastian Reinartz, Daniel Ulrich, Thorsten Fritzius, Luca Trovo, Salomé Roux, Ziyang Chen, Philippe Rondard and 7 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. GABAeNeuro · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Genetic implication of GABAFrontiers in pharmacology · 2025
    Review
  10. Monoallelic de novoScience advances · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. The role of GABAFrontiers in endocrinology · 2023
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 6 countries.

Pascal Dominic RemDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.
Vita SereikaiteCenter for Biopharmaceuticals, Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken, Copenhagen, Denmark.
Diego Fernández-FernándezDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.ORCID 0000-0003-1431-3705
Sebastian ReinartzDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.
Daniel UlrichDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.
Thorsten FritziusDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.ORCID 0000-0002-3597-6623
Luca TrovoDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.
Salomé RouxInstitut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France.ORCID 0000-0002-6106-4863
Ziyang ChenCenter for Biopharmaceuticals, Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken, Copenhagen, Denmark.
Philippe RondardInstitut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France.ORCID 0000-0003-1134-2738
Jean-Philippe PinInstitut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France.
Jochen SchwenkInstitute of Physiology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0003-3664-9795
Bernd FaklerInstitute of Physiology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-7264-6423
Martin GassmannDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.
Tania Rinaldi BarkatDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.ORCID 0000-0001-8650-0986
Kristian StrømgaardCenter for Biopharmaceuticals, Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken, Copenhagen, Denmark.ORCID 0000-0003-2206-4737
Bernhard BettlerDepartment of Biomedicine, Pharmazentrum, University of Basel, Basel, Switzerland.ORCID 0000-0003-0842-8207
University of Basel · CHUniversité de Montpellier · FRUniversity of Copenhagen · DKUniversity of Freiburg · DE

Funding

Swiss National Science Foundation 31003A-152970
6 · The paper itself

Abstract

Amyloid-β precursor protein (APP) regulates neuronal activity through the release of secreted APP (sAPP) acting at cell surface receptors. APP and sAPP were reported to bind to the extracellular sushi domain 1 (SD1) of GABA

Indexed as

Amyloid beta-PeptidesAmyloid beta-Protein Precursorgamma-Aminobutyric AcidNeuronsNeurotransmitter AgentsSyndactylyAmyloid beta-PeptidesAmyloid beta-Protein Precursorgamma-Aminobutyric AcidNeurotransmitter AgentsGABABG protein-coupled receptorsmouseneurosciencesoluble amyloid-β precursor protein

Identifiers

PMID36688536
PMCPMC9917443
OpenAlexW4317749634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.